Disease on EC 3.4.24.63 - meprin B

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Aspartic peptidase inhibitors: implications in drug development.
Design of potent aspartic protease inhibitors to treat various diseases.
Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality.
Alzheimer Disease
A Method for Induced-Fit Docking, Scoring, and Ranking of Flexible Ligands. Application to Peptidic and Pseudopeptidic beta-secretase (BACE 1) Inhibitors.
A novel approach to identifying beta-secretase inhibitors: bis-statine peptide mimetics discovered using structure and spot synthesis.
A Novel Immunotherapy for Alzheimer's Disease: Antibodies against the beta-Secretase Cleavage Site of APP.
A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein.
A novel substrate for analyzing Alzheimer's disease gamma-secretase.
A splice variant of beta-secretase deficient in the amyloidogenic processing of the amyloid precursor protein.
Activation of peroxisome proliferator-activated receptor delta suppresses BACE1 expression by up-regulating SOCS1 in a JAK2/STAT1-dependent manner.
Activation of protein kinase C modulates BACE1-mediated beta-secretase activity.
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.
Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer's Disease.
alpha- and beta-secretase: profound changes in Alzheimer's disease.
Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate.
Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.
Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576.
Apo and inhibitor complex structures of BACE (beta-secretase).
Apoptogenic interactions of plasmalemmal type-1 VDAC and A? peptides via GxxxG motifs induce Alzheimer's disease - a basic model of apoptosis?
Application of molecular framework-based data-mining method in the search for beta-secretase 1 inhibitors through drug repurposing.
Aspartic peptidase inhibitors: implications in drug development.
Assigning the protonation states of the key aspartates in beta-Secretase using QM/MM X-ray structure refinement.
Association between promoter polymorphisms in anterior pharynx-defective-1a and sporadic Alzheimer's disease in the North Chinese Han population.
Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent.
BACE (beta-secretase) modulates the processing of APLP2 in vivo.
BACE inhibitors as potential therapeutics for Alzheimer's disease.
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: Chromene, coumarin and quinoline.
BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
BACE1 and BACE2 enzymatic activities in Alzheimer's disease.
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.
BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens.
BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus.
BACE1 polymorphisms do not influence platelet membrane beta-secretase activity or genetic susceptibility for Alzheimer's disease in the Northern Irish population.
BACE1: the beta-secretase enzyme in Alzheimer's disease.
BACE2 as a new diabetes target: a patent review 2010 - 2012.
Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms.
Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease.
Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Beta-Secretase 1 (BACE1) Is Down-Regulated in Invasive Ductal Carcinoma of Breast.
Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.
Beta-secretase as a target for the treatment of Alzheimer's disease.
beta-Secretase as a therapeutic target for Alzheimer's disease.
beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations.
beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity.
Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain.
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease.
Beta-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease.
beta-Secretase, APP and Abeta in Alzheimer's disease.
Beta-secretase: structure, function, and evolution.
Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Caffeine Reverses Cognitive Impairment and Decreases Brain Amyloid-beta Levels in Aged Alzheimer's Disease Mice.
Cell biology, regulation and inhibition of beta-secretase (BACE-1).
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.
Chalcones Acting as Inhibitors of Cholinesterases, ?-Secretase and ?- Amyloid Aggregation and other Targets for Alzheimer's Disease: A Critical Review.
Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1).
Characterization of Drosophila aspartic proteases that induce the secretion of a Golgi-resident transferase, heparan sulfate 6-O-sulfotransferase.
Chia Seed Does Not Improve Cognitive Impairment in SAMP8 Mice Fed with High Fat Diet.
Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts.
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Combination of a modified scoring function with two-dimensional descriptors for calculation of binding affinities of bulky, flexible ligands to proteins.
Comparison of batch and perfusion culture in combination with pilot-scale expanded bed purification for the production of soluble recombinant beta-secretase.
Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase.
Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.
CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
CSF markers for incipient Alzheimer's disease.
Current updates on the regulation of beta-secretase movement as a potential restorative focus for management of Alzheimer's disease.
Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics.
Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes.
Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy.
Design of Curcumin and Flavonoid Derivatives with Acetylcholinesterase and Beta-Secretase Inhibitory Activities Using in Silico Approaches.
Design of potent aspartic protease inhibitors to treat various diseases.
Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease.
Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
Design, synthesis, in silico and in vitro screening of 1,2,4-thiadiazole analogues as non-peptide inhibitors of beta-secretase.
Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.
Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation.
Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid.
Ectodomain shedding of the amyloid precursor protein: cellular control mechanisms and novel modifiers.
Editorial. BACE or beta-secretase -a target for drug discovery for treatment of Alzheimer's disease.
Effect of mycelial extract of Clavicorona pyxidata on the production of amyloid beta-peptide and the inhibition of endogenous beta-secretase activity in vitro.
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease.
Emerging Alzheimer's disease therapies: inhibition of beta-secretase.
Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
Enhanced sleep reverses memory deficits and underlying pathology in Drosophila models of Alzheimer's disease.
Ensemble-Docking Approach on BACE-1: Pharmacophore Perception and Guidelines for Drug Design.
Evaluation of BACE1 Silencing in Cellular Models.
Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates.
Evidence for dimeric BACE-mediated APP processing.
Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease.
Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1).
Exploring 2D-QSAR for prediction of beta-secretase 1 (BACE1) inhibitory activity against Alzheimer's disease.
Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).
Expression analysis of BACE2 in brain and peripheral tissues.
Expression analysis of beta-secretase 1 (BACE1) and its naturally occurring antisense (BACE1-AS) in blood of epileptic patients.
Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer's disease.
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase.
Familial Alzheimer's Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-beta Protein Precursor Generated by beta-Secretase Cleavage.
Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.
Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis.
Functional plasticity in the substrate binding site of beta-secretase.
Generation of aggregation prone N-terminally truncated amyloid ? peptides by meprin ? depends on the sequence specificity at the cleavage site.
GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide.
Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease.
Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme.
High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease.
High resolution imaging study of interactions between the 37 kDa/67 kDa laminin receptor and APP, beta-secretase and gamma-secretase in Alzheimer's disease.
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
Human beta-secretase and Alzheimer's disease.
Human brain beta-secretase contains heparan sulfate glycoconjugates.
Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors.
Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors.
Identification of beta-secretase (BACE1) substrates using quantitative proteomics.
In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase.
In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
In silico study of peptide inhibitors against BACE 1.
In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain.
Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects.
Increased CSF- BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease.
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease.
Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.
Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease.
Inhibitors of Cathepsin B Improve Memory and Reduce {beta}-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, {beta}-Secretase Site of the Amyloid Precursor Protein.
Insights from modeling the tertiary structure of human BACE2.
Interaction models of substrate peptides and beta-secretase studied by NMR spectroscopy and molecular dynamics simulation.
Involvement of proteases in glycosyltransferase secretion: Alzheimer's beta-secretase-dependent cleavage and a following processing by an aminopeptidase.
JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1.
Lack of evidence to support the association of polymorphisms within the alpha- and beta-secretase genes (ADAM10/BACE1) with Alzheimer's disease.
Large-scale purification of human BACE expressed in mammalian cells and removal of the prosegment with HIV-1 protease to improve crystal diffraction.
Lentivirus-expressed siRNA vectors against Alzheimer disease.
Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients.
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase.
Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence.
Memapsin 2 (beta-secretase) as a therapeutic target.
Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2.
Memapsin 2, a drug target for Alzheimer's disease.
Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
Metalloprotease meprin ? is activated by transmembrane serine protease matriptase-2 at the cell surface thereby enhancing APP shedding.
microRNAs in CNS disorders.
Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.
Modeling the protonation states of the catalytic aspartates in beta-secretase.
Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase.
Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays.
Neuroproteases in peptide neurotransmission and neurodegenerative diseases: applications to drug discovery research.
Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death.
Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.
NF{kappa}B-dependent Control of BACE1 Promoter Transactivation by A{beta}42.
NMR studies reveal a novel mode for hFADD to bind with the unstructured hRTN3 which initiates the ER-stress activated apoptosis.
Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells.
Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein.
pH-dependent conformational dynamics of beta-secretase 1: A molecular dynamics study.
Phenolic Profiles, Antioxidant, and Inhibitory Activities of Kadsura heteroclita (Roxb.) Craib and Kadsura coccinea (Lem.) A.C. Sm.
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.
Phosphorylation regulates intracellular trafficking of beta-secretase.
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease.
Platelet beta-secretase activity is increased in Alzheimer's disease.
Post-translational processing of beta-secretase in Alzheimer's disease.
Prediction of the tertiary structure of the beta-secretase zymogen.
Progress in the development of beta-secretase inhibitors for Alzheimer's disease.
Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells.
Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network.
Proteolytic cascade in the amyloidogenesis of Alzheimer's disease.
Purification and cloning of amyloid precursor protein beta-secretase from human brain.
QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease.
Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective ?-secretase 1 Imaging, in Non-human Primate Brain.
Rapid and Direct Transport of Cell Surface APP to the Lysosome defines a novel selective pathway.
Recent Developments of Structure Based beta-Secretase Inhibitors for Alzheimer's Disease.
Reduction of A? Generation by Schisandrin B through Restraining Beta-Secretase 1 Transcription and Translation.
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I.
Regulation of amyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N).
Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons.
Regulation of secretases by all-trans-retinoic acid.
Reticulon proteins: emerging players in neurodegenerative diseases.
Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein.
Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate.
RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro.
Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells.
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease.
Simple structure-based approach for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's disease.
Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity.
Splice variants of the Alzheimer's disease beta-secretase, BACE1.
Structure-based calculation of drug efficiency indices.
Study of memapsin 2 (beta-secretase) and strategy of inhibitor design.
Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases.
Swedish mutation within amyloid precursor protein modulates global gene expression towards the pathogenesis of Alzheimer's disease.
Synthesis of tetramic and tetronic acids as beta-secretase inhibitors.
Synthesis, In Silico and In Vitro Evaluation for Acetylcholinesterase and BACE-1 Inhibitory Activity of Some N-Substituted-4-Phenothiazine-Chalcones.
Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.
Temporal Effects of Neuron-specific beta-secretase 1 (BACE1) Knock-in on the Mouse Brain Metabolome: Implications for Alzheimer's Disease.
The Alzheimer's disease beta-secretase enzyme, BACE1.
The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
The influence of BACE1 on macrophage recruitment and activity in the injured peripheral nerve.
The metabolism of beta-amyloid converting enzyme and beta-amyloid precursor protein processing.
The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression and secretion of the amyloid precursor protein.
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
The regulation of beta-secretase by cholesterol and statins in Alzheimer's disease.
The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology.
The role of heparan sulfate in the generation of Abeta.
The search for drug leads targeted to the beta-secretase: an example of the roles of computer assisted approaches in drug discovery.
The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway.
Therapeutic approaches to Alzheimer's disease.
Translational regulation of BACE-1 expression in neuronal and non-neuronal cells.
Untangling Alzheimer's disease with beta-secretase inhibitors.
Variation in RTN3 and PPIL2 Genes Does not Influence Platelet Membrane beta-Secretase Activity or Susceptibility to Alzheimer's Disease in the Northern Irish Population.
Visualization of beta-secretase cleavage in living cells using a genetically encoded surface-displayed FRET probe.
Why does beta-secretase zymogen possess catalytic activity? Molecular modeling and molecular dynamics simulation studies.
Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria?
[Application of an R-group search strategy into three-dimensional quantitative structure-activity relationship of HEA beta-secretase inhibitors and molecular virtual screening].
[Effect of PNS on the activity and content of BACE1 in the brain of SAMP8 mice with Alzheimer's disease].
Amyloidosis
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.
Amyotrophic Lateral Sclerosis
Inhibition of Amyloid Precursor Protein Beta-Secretase Cleavage Site Affects Survival and Motor Functions of Amyotrophic Lateral Sclerosis Transgenic Mice.
Brain Injuries, Traumatic
Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1).
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.
Brain Ischemia
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
Breast Neoplasms
Aspartic peptidase inhibitors: implications in drug development.
Carcinoma
Structure of the mouse metalloprotease meprin beta gene (Mep1b): alternative splicing in cancer cells.
Carcinoma, Ductal
Beta-Secretase 1 (BACE1) Is Down-Regulated in Invasive Ductal Carcinoma of Breast.
Crohn Disease
Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading.
Dementia
Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
Dementia, Vascular
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Down Syndrome
Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.
Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.
Glomerulonephritis
Downregulated expression in high IgA (HIGA) mice and the renal protective role of meprinbeta.
Metalloprotease meprin beta in rat kidney: glomerular localization and differential expression in glomerulonephritis.
Hypertension
Aspartic peptidase inhibitors: implications in drug development.
Design of potent aspartic protease inhibitors to treat various diseases.
Infections
Aspartic peptidase inhibitors: implications in drug development.
Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to beta-secretase.
Ischemic Attack, Transient
Increased beta-secretase activity and expression in rats following transient cerebral ischemia.
Ischemic Stroke
Mutant ubiquitin-mediated beta-secretase stability via activation of caspase-3 is related to beta-amyloid accumulation in ischemic striatum in rats.
Leukemia-Lymphoma, Adult T-Cell
Design of potent aspartic protease inhibitors to treat various diseases.
Malaria
Aspartic peptidase inhibitors: implications in drug development.
Design of potent aspartic protease inhibitors to treat various diseases.
Melanoma
Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity.
Memory Disorders
Inhibitors of Cathepsin B Improve Memory and Reduce {beta}-Amyloid in Transgenic Alzheimer Disease Mice Expressing the Wild-type, but Not the Swedish Mutant, {beta}-Secretase Site of the Amyloid Precursor Protein.
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Neoplasm Metastasis
Aspartic peptidase inhibitors: implications in drug development.
Neoplasms
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.
Meprin B: transcriptional and posttranscriptional regulation of the meprin beta metalloproteinase subunit in human and mouse cancer cells.
Nardilysin in human brain diseases: both friend and foe.
Structure of the mouse metalloprotease meprin beta gene (Mep1b): alternative splicing in cancer cells.
Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemia-reperfusion injury in mice.
Neuroblastoma
A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets.
Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production.
Down-regulation of seladin-1 increases bace1 levels and activity through enhanced GGA3 depletion during apoptosis.
Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme.
Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein.
Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta-amyloid secretion.
Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression.
Pulse-chase experiments revealed beta-secretase cleavage from immature full-length amyloid precursor protein harboring the Swedish mutation. Implications for distinct pathways.
Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway.
Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides.
Up-regulation of the {alpha}-secretase ADAM10 by retinoic acid receptors and acitretin.
Neurodegenerative Diseases
A pathogenic PrP mutation and doppel interfere with polarized sorting of the prion protein.
Neuroactive venom compounds obtained from Phlogiellus bundokalbo as potential leads for neurodegenerative diseases: insights on their acetylcholinesterase and beta-secretase inhibitory activities in vitro.
Neuroinflammatory Diseases
Contrasting effects of acute and long-term corticosterone treatment on amyloid-?, beta-secretase 1 expression, and nuclear factor kappa B nuclear translocation.
From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis.
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Paraparesis, Tropical Spastic
Design of potent aspartic protease inhibitors to treat various diseases.
Periodontitis
Periodontitis Deteriorates Cognitive Function and Impairs Neurons and Glia in a Mouse Model of Alzheimer's Disease.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy.
Prion Diseases
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.
Reperfusion Injury
Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemia-reperfusion injury in mice.
Retinal Diseases
Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death.
Seizures
Association between BACE1 gene polymorphisms and focal seizures in a Chinese Han population.
Sepsis
The Role of Secretase Pathway in Long-term Brain Inflammation and Cognitive Impairment in an Animal Model of Severe Sepsis.
Skin Diseases
Syndecan-1 shedding by meprin ? impairs keratinocyte adhesion and differentiation in hyperkeratosis.
Spinal Cord Diseases
Design of potent aspartic protease inhibitors to treat various diseases.
Stroke
Caspase inhibition attenuates accumulation of beta-amyloid by reducing beta-secretase production and activity in rat brains after stroke.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Teratocarcinoma
Meprin B: transcriptional and posttranscriptional regulation of the meprin beta metalloproteinase subunit in human and mouse cancer cells.
Thiamine Deficiency
Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides.